Physician profile
Indranil Dasgupta
NPI 1205856143
$5,456.38
in general payments reported to CMS, 2019-2025
34 companies · $1,044 in 2025
The $1,044 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,181 · 2020: $597 · 2021: $102 · 2022: $610 · 2023: $1,146 · 2024: $777 · 2025: $1,044.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,967.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,967.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,193.65 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $623.07 | 2019-2025 | |
| Amgen INC. | $553.51 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $462.00 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $388.29 | 2019-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $367.62 | 2019-2025 | Wainua, Farxiga |
| Boston Scientific Corporation | $315.87 | 2023-2025 | Watchman Flx, Watchman Access System, Bodyguardian |
| Boehringer Ingelheim Pharmaceuticals, INC. | $294.82 | 2019-2025 | Jardiance |
| Impulse Dynamics (USA) INC. | $171.23 | 2020-2025 | Optimizer, Optimizer |
| Regeneron Healthcare Solutions, INC. | $129.21 | 2019 | |
| Akcea Therapeutics, INC. | $122.88 | 2020 | |
| Kiniksa Pharmaceuticals, LTD. | $99.17 | 2022-2023 | Arcalyst |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $82.59 | 2019-2022 | |
| Bridgebio Pharma, INC. | $79.89 | 2025 | Attruby |
| Lexicon Pharmaceuticals, INC. | $67.69 | 2023-2024 | Inpefa |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $56.50 | 2022-2023 | Injectafer |
| Amarin Pharma, INC. | $42.54 | 2019-2022 | |
| Scpharmaceuticals INC. | $40.69 | 2025 | |
| Abbott Laboratories | $37.74 | 2022-2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| Alnylam Pharmaceuticals INC. | $37.36 | 2023-2025 | Amvuttra, Onpattro |
| Esperion Therapeutics, INC. | $29.82 | 2022-2024 | Nexletol |
| Atricure, INC. | $26.60 | 2023 | |
| Astellas Pharma US INC | $25.39 | 2019-2020 | |
| Exeltis, USA INC. | $23.10 | 2023 | Slynd |
| Abiomed | $21.03 | 2024 | Impella |
| Edwards Lifesciences Corporation | $20.71 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Preventice Services, LLC | $20.22 | 2019 | |
| Novo Nordisk INC | $19.48 | 2023 | Rybelsus, Ozempic |
| Inspire Medical Systems, INC. | $19.37 | 2023 | Inspire |
| Heartflow, INC. | $18.81 | 2025 | |
| Sanofi-Aventis U.S. LLC | $18.43 | 2019 | |
| Merck Sharp & Dohme LLC | $16.56 | 2023 | Verquvo |
| Kiniksa Pharmaceuticals International, Plc | $15.54 | 2024 | Arcalyst |
| Bardy Diagnostics, INC. | $15.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Indranil Dasgupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.